Does State Medicaid Cover Prometrium?

Why Medicaid Coverage of Prometrium Is Not Uniform

Each state administers its own Medicaid program under federal guidelines, which means drug formularies are not identical across state lines. The Medicaid Drug Rebate Program (MDRP), established under the Omnibus Budget Reconciliation Act of 1990, requires participating manufacturers to provide rebates to state Medicaid agencies in exchange for formulary inclusion. Prometrium's manufacturer participates in this program, so the drug is technically available in every state Medicaid system. That does not mean it is automatically covered without restrictions.

States use Pharmacy and Therapeutics (P&T) committees to evaluate drugs and assign formulary positions. Because generic micronized progesterone capsules (100 mg and 200 mg) have been available since 2005 and are rated AB-equivalent to Prometrium by the FDA, most state P&T committees place the generic on their preferred drug lists and classify brand Prometrium as non-preferred or exclude it outright. A 2023 analysis by the Medicaid and CHIP Payment and Access Commission (MACPAC) noted that generic substitution policies are one of the primary cost-containment tools across all 50 state Medicaid programs.

If your prescriber writes "Prometrium" with "dispense as written" (DAW), the pharmacy must fill the brand. But many state Medicaid programs will deny the brand claim unless a prior authorization is on file justifying why the generic is not appropriate. This single distinction accounts for the majority of Prometrium coverage denials on Medicaid.

How Prometrium Works and Why It Is Prescribed

Micronized progesterone is bioidentical to the progesterone produced by the human ovary. It serves a specific clinical purpose: protecting the uterine lining (endometrium) from the proliferative effects of estrogen therapy. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (N=875, JAMA 1995) demonstrated that micronized progesterone combined with conjugated equine estrogens prevented endometrial hyperplasia while producing a more favorable lipid profile than medroxyprogesterone acetate (MPA).

The FDA-approved prescribing information for Prometrium specifies two indications: prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens, and treatment of secondary amenorrhea. The standard dose for endometrial protection is 200 mg orally at bedtime for 12 consecutive days per 28-day cycle when used cyclically, or 100 mg daily when used continuously.

This matters for Medicaid coverage because the approved indication is narrow. Off-label uses (luteal phase support in fertility treatment, for example) may face additional coverage barriers.

Formulary Tier Placement Across States

State Medicaid formularies generally use a tiered structure. Tier 1 (Preferred Generic) carries the lowest copay, while Tier 3 or higher (Non-Preferred Brand) may require both prior authorization and a higher cost-share for beneficiaries in expansion populations.

Generic micronized progesterone sits on Tier 1 or Preferred Generic in the majority of state Medicaid preferred drug lists (PDLs). Brand-name Prometrium, where it appears at all, is typically classified as Tier 3 or Non-Preferred Brand. Some states (including Texas, Florida, and New York) publish their PDLs online. A review of publicly available 2025 PDLs shows:

• New York Medicaid (Fee-for-Service): Generic micronized progesterone is preferred. Brand Prometrium requires prior authorization.
• California Medi-Cal: Generic is on the Contract Drug List. Brand requires a Treatment Authorization Request (TAR).
• Texas Medicaid: Generic is preferred. Brand requires prior authorization through the Vendor Drug Program.
• Ohio Medicaid: Generic preferred on the Unified PDL. Brand Prometrium is non-preferred with PA required.

Because Medicaid managed care organizations (MCOs) may apply their own formulary overlays, a beneficiary enrolled in an MCO plan could face different rules than someone on fee-for-service Medicaid in the same state. Checking the specific MCO formulary is necessary in every case. The Centers for Medicare & Medicaid Services (CMS) requires MCOs to maintain coverage that is at least as broad as the state's benchmark, but the specific tier and utilization management tools can vary.

Prior Authorization Criteria for Prometrium on Medicaid

Prior authorization (PA) for brand Prometrium on Medicaid typically requires the prescriber to demonstrate one of the following:

Therapeutic failure on generic. The patient tried generic micronized progesterone and experienced a documented adverse effect (breakthrough bleeding, allergic reaction to an inactive ingredient, inadequate symptom control). A 2018 study in the Journal of Clinical Pharmacy and Therapeutics found that while the active ingredient is identical, differences in inactive ingredients (peanut oil in the original Prometrium formulation, for instance) can affect tolerability for patients with specific allergies.

Allergy or contraindication. The patient has a documented allergy to an excipient in available generic formulations. This is the most straightforward PA approval pathway.

Medical necessity documentation. The prescriber provides clinical rationale explaining why the brand product is medically necessary. General preference or patient request alone typically does not meet state Medicaid PA thresholds.

PA turnaround times are governed by federal regulation. Under 42 CFR § 438.210, Medicaid MCOs must process standard prior authorization requests within 14 calendar days and expedited requests within 72 hours. Fee-for-service programs follow state-specific timelines, though most mirror these federal benchmarks.

The practical recommendation: if generic micronized progesterone is tolerated, use it. The active ingredient is the same. The cost to the Medicaid program drops from approximately $180/month (brand) to roughly $20 to $45/month (generic), which makes generic the default choice for every state formulary.

Step Therapy Requirements

Step therapy (also called "fail-first") is a related but distinct utilization management tool. Where prior authorization asks the prescriber to justify the drug at the time of prescribing, step therapy requires the patient to have already tried and failed a preferred alternative before the non-preferred drug will be covered.

For Prometrium specifically, step therapy on Medicaid almost always means trying generic micronized progesterone first. Some state Medicaid programs also require a trial of medroxyprogesterone acetate (MPA, brand name Provera) before approving even generic micronized progesterone, though this is less common and clinically questionable given that the PEPI trial showed micronized progesterone to be metabolically superior to MPA.

According to the Endocrine Society's 2015 Clinical Practice Guideline on the treatment of symptoms of menopause, micronized progesterone is preferred over synthetic progestins for endometrial protection because of its neutral-to-favorable effect on lipids and lower associated breast cancer risk in observational data. If your state Medicaid program requires MPA as a first step before micronized progesterone, your prescriber can cite this guideline in a step therapy exception request.

The 2022 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) reinforced this preference, stating that "micronized progesterone may have a better risk profile than synthetic progestins with respect to breast cancer risk and cardiovascular effects." This is strong evidence for an exception request.

How to Appeal a Medicaid Denial for Prometrium

If Medicaid denies coverage of Prometrium (brand or generic), you have a right to appeal. The process follows this sequence:

Step 1: Internal appeal to the MCO. If enrolled in a Medicaid managed care plan, file an internal appeal within the timeframe specified in the denial notice (typically 30 to 60 days). The MCO must respond within 30 days for standard appeals.

Step 2: State fair hearing. If the MCO upholds the denial, or if you are on fee-for-service Medicaid, request a state fair hearing. Under 42 USC § 1396a(a)(3), every state Medicaid program must provide a fair hearing to any individual whose claim is denied or not acted upon promptly. You typically have 90 to 120 days from the denial to request this hearing, though timelines vary by state.

Step 3: Gather clinical documentation. The strongest appeals include a letter of medical necessity from the prescribing physician, documentation of generic trial and failure (dates, doses, adverse effects), relevant clinical guidelines (NAMS, Endocrine Society), and the patient's complete medication history.

Step 4: Request continuation of benefits. If you were previously receiving the medication and it was denied upon renewal, you can request that benefits continue during the appeal process by filing your appeal before the effective date of the denial.

A 2021 report from the HHS Office of Inspector General found that a significant proportion of Medicaid MCO prior authorization denials were overturned on appeal, suggesting that initial denials are not always clinically well-founded. Do not assume a first denial is final.

Generic vs. Brand: What Medicaid Beneficiaries Should Know

The FDA's Orange Book lists multiple generic micronized progesterone products rated therapeutically equivalent (AB rating) to Prometrium. These generics must meet the same bioequivalence standards: 90% confidence interval for AUC and Cmax within 80% to 125% of the reference product.

There is one clinically relevant difference worth noting. The original Prometrium formulation uses peanut oil as a suspension vehicle. Some generic versions also use peanut oil, while others use alternative oils. For patients with peanut allergy, this excipient distinction is medically significant and represents a valid basis for requesting a specific formulation through prior authorization.

For most patients, generic micronized progesterone is clinically interchangeable with brand Prometrium. The American College of Obstetricians and Gynecologists (ACOG) has not issued guidance distinguishing between brand and generic micronized progesterone for the indication of endometrial protection.

Cost Comparison: What You Pay on Medicaid

Medicaid beneficiaries in most states pay nominal copays. Under federal law, copays for preferred drugs cannot exceed $4 for most Medicaid populations, and many states set them at $1 to $3 or waive them entirely for certain populations (pregnant women, children, individuals below the federal poverty level).

The cost structure breaks down roughly as follows:

• Generic micronized progesterone (Preferred Tier): $0 to $3 copay per fill in most states
• Brand Prometrium (Non-Preferred, if approved through PA): $4 to $8 copay in states that apply higher-tier cost-sharing
• Cash-pay without insurance: approximately $45/month for generic, $180/month for brand

For Medicaid expansion populations (adults with incomes up to 138% FPL in expansion states), cost-sharing cannot exceed 5% of household income per quarter. This effectively limits total out-of-pocket drug costs regardless of formulary tier.

Using Manufacturer Savings Cards with Medicaid

Federal anti-kickback statute (42 USC § 1320a-7b) prohibits pharmaceutical manufacturers from offering copay assistance to patients whose prescriptions are paid by federal healthcare programs, including Medicaid. This means manufacturer savings cards, coupons, and copay cards for Prometrium cannot be applied to Medicaid prescriptions.

This rule exists because copay assistance on a federally funded prescription could be interpreted as an inducement to use a more expensive product when a cheaper alternative is available. The prohibition applies to Medicaid, Medicare, TRICARE, and other federal programs.

Some manufacturers offer separate Patient Assistance Programs (PAPs) for uninsured or underinsured patients that operate differently from copay cards. These programs provide the drug at no cost and do not interact with the insurance claim. However, Medicaid beneficiaries are generally not eligible for PAPs because they already have drug coverage.

State-by-State Variability: What Drives the Differences

The wide variation in Prometrium coverage across state Medicaid programs reflects several structural factors:

Rebate negotiations. States negotiate supplemental rebates with manufacturers beyond the federal minimum. These negotiations are confidential, but the resulting net cost influences whether a drug lands on the preferred list.

P&T committee composition. Each state's P&T committee includes different physicians and pharmacists with different clinical perspectives. A committee with more gynecologists or menopause specialists may be more likely to prefer micronized progesterone over MPA.

Managed care penetration. In states where most Medicaid beneficiaries are enrolled in MCOs (which includes the majority of states), the MCO's own formulary and PA criteria may supersede the state's fee-for-service PDL. As of 2024, over 70% of Medicaid beneficiaries nationally were enrolled in comprehensive managed care plans, according to CMS data.

Budget pressure. States facing budget constraints may apply more restrictive utilization management across their entire formulary, not just for high-cost specialty drugs.

The practical takeaway: always check your specific state's Medicaid formulary (available on your state Medicaid agency's website or through the MCO's member portal) rather than assuming national uniformity. Your prescriber's office can also run a real-time eligibility and formulary check at the point of prescribing.

When to Talk to Your Prescriber About Coverage Issues

Contact your prescriber's office before the prescription is sent to the pharmacy if you anticipate coverage problems. The prescriber can run a formulary check through the electronic health record, write for generic micronized progesterone by default (which avoids most PA requirements), or preemptively submit a PA if brand Prometrium is clinically necessary. Many denials result from prescriptions written for the brand name when the prescriber intended the generic, a simple communication gap that wastes days in the PA process.